Do combined oral contraceptives (COC) improve hirsutism in women with polycystic ovary syndrome (PCOS)?

Combined Oral Contraceptives for PCOS-Related Hirsutism

Yes, combined oral contraceptives (COCs) are effective for treating hirsutism in women with PCOS and should be used as first-line pharmacological therapy. 1

Primary Recommendation

The 2013 Endocrine Society PCOS Guidelines explicitly recommend hormonal contraceptives (oral contraceptives, patch, or vaginal ring) as first-line management for both menstrual abnormalities and hirsutism/acne in PCOS, treating these problems concurrently 1. This is reinforced by the 2008 Endocrine Society Hirsutism Guidelines, which support OCPs as a primary treatment option 2.

Mechanism and Efficacy

COCs work through two key mechanisms:

• Suppression of ovarian androgens: The progestin component suppresses LH levels, reducing ovarian androgen production
• Increased SHBG: The estrogen component increases sex hormone-binding globulin, thereby reducing bioavailable androgens 1

Evidence of Effectiveness

A 2018 systematic review and meta-analysis demonstrated that COC use for 3-12 months significantly:

• Decreased Ferriman-Gallwey hirsutism scores
• Increased SHBG levels
• Reduced total testosterone, free testosterone, androstenedione, and DHEAS levels 3

Long-term use (6-12 months) is more effective than short-term treatment for improving hirsutism 3. A 2018 long-term study showed 85.1% of patients reported improvement in hirsutism with suppressive therapy, with the majority requiring at least 6 months of treatment and continuing improvement with longer duration 4.

Formulation Selection

No single COC formulation is definitively superior to others for hirsutism treatment 2, 1. However, there are theoretical considerations:

Progestin Type

• Avoid highly androgenic progestins: Levonorgestrel has the most androgenic activity and may adversely affect metabolic biomarkers, though one small trial showed no difference in hirsutism efficacy compared to desogestrel 2
• Consider low-androgenicity progestins: Norgestimate and desogestrel are reasonable options
• Antiandrogenic progestins: Drospirenone and cyproterone acetate (CPA) have theoretical advantages. COCs containing CPA for 12 months showed the strongest effect in improving hirsutism 3

Estrogen Dose

Both 30-35 µg and 20 µg ethinyl estradiol preparations can be used for ovarian androgen suppression 2. While no clinical trials exist specifically for 20 µg preparations in hirsutism, they appear as effective as higher doses for acne 2.

Combination Therapy Considerations

Adding Antiandrogens to COCs

The 2008 Endocrine Society meta-analysis found no significant additional benefit when antiandrogens were added to OCPs alone for most patients 2. However:

• For severe hirsutism: A 2018 double-blind RCT showed OCP + bicalutamide (50 mg/d) was significantly more effective than OCP alone in reducing severe hirsutism 5
• OCP + spironolactone: A 2018 study demonstrated greater efficacy with combination therapy (OCP + spironolactone 100-200 mg/d in divided doses) than either drug alone, with 85.1% patient satisfaction 4

Metformin Combination

Recent high-quality evidence challenges the routine addition of metformin:

• The 2025 COMET-PCOS trial (double-blind RCT in women with PCOS and obesity) found no difference in hirsutism improvement between COCPs alone, metformin alone, or combination therapy 6
• A 2024 meta-analysis confirmed no differences in hirsutism when comparing metformin vs COCP, or COCP vs combination treatment 7
• A 2021 study showed combining COCs with laser hair removal achieved better quality of life outcomes than combining metformin with laser 8

Do not routinely add metformin to COCs specifically for hirsutism treatment—reserve metformin for metabolic indications (insulin resistance, prediabetes, weight management in those with BMI >25 kg/m²) 7, 9.

Metabolic Safety Considerations

Screen for contraindications to COC use before prescribing 1. Recent evidence is reassuring regarding metabolic concerns:

• The 2025 COMET-PCOS trial found low-dose COCPs (20 µg ethinyl estradiol) did not increase prevalence of metabolic syndrome in women with PCOS and obesity over 24 weeks 6
• COCPs actually decreased waist circumference, BMI, and android fat mass in this population 6
• Long-term studies in healthy women show HC use does not increase incidence of type 2 diabetes 1

However, COCPs are inferior to metformin for insulin sensitivity—metformin lowered insulin and triglycerides compared to COCPs 7. In women with significant metabolic comorbidities where COCs are contraindicated, consider metformin with lifestyle changes as second-line therapy 10.

Treatment Timeline and Expectations

• Minimum treatment duration: 6 months before assessing efficacy 4, 10
• Optimal duration: 6-12 months for maximal hirsutism improvement 3
• Continued improvement: Patient satisfaction continues to increase with treatment duration beyond 6 months 4
• Maintenance: Treatment must be continued long-term, as hirsutism typically recurs after discontinuation

Clinical Pitfalls to Avoid

1. Stopping treatment too early: Many patients and providers become discouraged before the 6-month minimum treatment period
2. Unrealistic expectations: Counsel patients that hair growth cycles mean visible improvement takes months
3. Ignoring severity: Mild hirsutism may respond to COCs alone, but moderate-to-severe hirsutism often requires combination with antiandrogens (spironolactone 100-200 mg/d) 10
4. Overlooking cosmetic measures: COCs reduce new hair growth but don't remove existing hair—combine with mechanical hair removal methods for faster cosmetic improvement 2
5. Prescribing metformin for hirsutism alone: Recent evidence shows no added benefit for hirsutism; reserve for metabolic indications 6, 7

Algorithm for Treatment Selection

For all PCOS women with hirsutism:

1. Screen for COC contraindications (cardiovascular risk factors, thrombophilia, migraine with aura, etc.)
2. If no contraindications → Start COC (any formulation; consider avoiding levonorgestrel; CPA-containing products may offer slight advantage)
3. Assess severity and patient distress level

Based on hirsutism severity:

• Mild hirsutism → COC alone + cosmetic hair removal methods
• Moderate-to-severe hirsutism → COC + spironolactone (100-200 mg/d in divided doses) 4, 10
• Very severe/refractory hirsutism → Consider COC + bicalutamide (50 mg/d) under specialist guidance 5

If COCs contraindicated:

• Metformin + lifestyle modification (for metabolic benefits)
• Antiandrogen (spironolactone) + reliable non-hormonal contraception
• Cosmetic/mechanical hair removal as primary approach

Reassess at 6 months minimum—continue treatment if improving, as benefits increase with duration 3, 4.